Posted: August 23, 2021 / 6:49 AM EDT / Updated: August 23, 2021 / 6:49 AM EDT
(CBS) — The American Academy of Pediatrics has released a new recommendation for the treatment of a respiratory infection known as RSV. This comes after an unusual rise in cases in infants and children.
RSV Rising Nationwide, Especially in Southern States, During Unlikely Season
The physician group recommends the use of the antibody Palivizumab to treat infants at increased risk of serious illnesses such as bronchiolitis or pneumonia.
“Palivizumab was licensed by the Food and Drug Administration in June 1998 for the reduction of severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in children at increased risk of serious illness. Since that time, the American Academy of Pediatrics has updated its guidelines for the use of palivizumab four times as additional data became available to better understand infants and young children at greatest risk of hospitalization due to RSV infection. ,” the organization wrote in a statement.
RSV cases usually peak in the fall and winter, but have been increasing since the spring. The organization supports this treatment during this atypical intermediate season and will re-evaluate its interim guidance on a monthly basis.
You can read the full recommendation by clicking here.